87 related articles for article (PubMed ID: 33316767)
1. Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response.
Zou F; Abu-Sbeih H; Ma W; Peng Y; Qiao W; Wang J; Shah AY; Glitza Oliva IC; Piha-Paul SA; Thompson JA; Zhang HC; Thomas AS; Wang Y
J Natl Compr Canc Netw; 2020 Dec; 19(6):700-708. PubMed ID: 33316767
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.
Abu-Sbeih H; Ali FS; Alsaadi D; Jennings J; Luo W; Gong Z; Richards DM; Charabaty A; Wang Y
J Immunother Cancer; 2018 Dec; 6(1):142. PubMed ID: 30518410
[TBL] [Abstract][Full Text] [Related]
3. Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer.
Liu C; Shatila M; Mathew A; Machado AP; Thomas A; Zhang HC; Thomas AS; Faleck D; Funchain P; Philpott J; Grivas P; Obeid M; Carbonnel F; Wang Y
J Cancer; 2023; 14(10):1913-1919. PubMed ID: 37476185
[No Abstract] [Full Text] [Related]
4. Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
Bonanno L; Lorenzi M; Massa D; De Nuzzo M; Angerilli V; Zingone F; Barberio B; Russi A; Girardi F; Ferro A; Dal Maso A; Frega S; Pasello G; Dei Tos AP; Coppola M; Fassan M; Savarino EV; Guarneri V
Oncologist; 2024 Jan; 29(1):e118-e130. PubMed ID: 37603442
[TBL] [Abstract][Full Text] [Related]
5. Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis.
Saji A; Chopra M; Jacob J; Altan M; Alhalabi O; Shah AY; Qiao W; Wang Y; Thomas A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5841-5852. PubMed ID: 36585982
[TBL] [Abstract][Full Text] [Related]
6. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis.
Abu-Sbeih H; Ali FS; Luo W; Qiao W; Raju GS; Wang Y
J Immunother Cancer; 2018 Sep; 6(1):95. PubMed ID: 30253811
[TBL] [Abstract][Full Text] [Related]
7. Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways.
Sleiman J; Brand RM; Pai R; Brand RE; Rhee J; Schwartz M; Davar D
Clin J Gastroenterol; 2023 Oct; 16(5):680-684. PubMed ID: 37452993
[TBL] [Abstract][Full Text] [Related]
8. Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis.
Kono M; Shatila M; Xu G; Lu Y; Mathew A; Mohajir W; Varatharajalu K; Qiao W; Thomas AS; Wang Y
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190257
[TBL] [Abstract][Full Text] [Related]
9. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis.
Zou F; Wang X; Glitza Oliva IC; McQuade JL; Wang J; Zhang HC; Thompson JA; Thomas AS; Wang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436487
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors.
Thomas AS; Ma W; Wang Y
N Engl J Med; 2021 Feb; 384(6):581-583. PubMed ID: 33567198
[No Abstract] [Full Text] [Related]
11. Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases.
Sun W; Lirio RA; Schneider J; Aubrecht J; Kadali H; Baratta M; Gulati P; Suri A; Lin T; Vasudevan R; Rosario M
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):734-747. PubMed ID: 33331142
[TBL] [Abstract][Full Text] [Related]
12. Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases.
Singh S; Heien HC; Sangaralingham L; Shah ND; Lai JC; Sandborn WJ; Moore AA
Inflamm Bowel Dis; 2021 Oct; 27(10):1626-1633. PubMed ID: 33325507
[TBL] [Abstract][Full Text] [Related]
13. Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease.
Yamamoto-Furusho JK; Bosques-Padilla FJ; Martínez-Vázquez MA;
Rev Gastroenterol Mex (Engl Ed); 2021; 86(1):70-85. PubMed ID: 33317930
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy induced enterocolitis and gastritis - What to do and when?
Cheung VTF; Brain O
Best Pract Res Clin Gastroenterol; 2020; 48-49():101703. PubMed ID: 33317787
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.
Pinato DJ; Fessas P; Sapisochin G; Marron TU
Hepatology; 2021 Jul; 74(1):483-490. PubMed ID: 33369758
[No Abstract] [Full Text] [Related]
16. Purpurin binding interacts with LHPP protein that inhibits PI3K/AKT phosphorylation and induces apoptosis in colon cancer cells HCT-116.
Li Z; Zhou X; Zhu H; Song X; Gao H; Niu Z; Lu J
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22665. PubMed ID: 33368780
[TBL] [Abstract][Full Text] [Related]
17. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
Kopetz S; Guthrie KA; Morris VK; Lenz HJ; Magliocco AM; Maru D; Yan Y; Lanman R; Manyam G; Hong DS; Sorokin A; Atreya CE; Diaz LA; Allegra C; Raghav KP; Wang SE; Lieu CH; McDonough SL; Philip PA; Hochster HS
J Clin Oncol; 2021 Feb; 39(4):285-294. PubMed ID: 33356422
[TBL] [Abstract][Full Text] [Related]
18. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
Estrada-Bernal A; Le AT; Doak AE; Tirunagaru VG; Silva S; Bull MR; Smaill JB; Patterson AV; Kim C; Liu SV; Doebele RC
Clin Cancer Res; 2021 Mar; 27(5):1463-1475. PubMed ID: 33355298
[TBL] [Abstract][Full Text] [Related]
19. Recurrent COVID-19 in a Patient With Ulcerative Colitis on Vedolizumab Therapy.
Crouwel F; Waaijenberg-Warmenhoven P; Buiter HJC; de Boer NK
J Crohns Colitis; 2021 Jul; 15(7):1244-1245. PubMed ID: 33350449
[No Abstract] [Full Text] [Related]
20. An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis.
Iacucci M; Smith SCL; Bazarova A; Shivaji UN; Bhandari P; Cannatelli R; Daperno M; Ferraz J; Goetz M; Gui X; Hayee B; De Hertogh G; Lazarev M; Li J; Nardone OM; Parra-Blanco A; Pastorelli L; Panaccione R; Occhipinti V; Rath T; Tontini GE; Vieth M; Villanacci V; Zardo D; Bisschops R; Kiesslich R; Ghosh S
Gastroenterology; 2021 Apr; 160(5):1558-1569.e8. PubMed ID: 33347880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
